Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
7Customers
3Debt Items
17Related Chains
Source-Backed Evidence Depth
Ovid Therapeutics Inc. (OVID) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
1Distinct source URLs
4High confidence
0.738Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from LGND graph: Reciprocal relationship from OVID graph: Reciprocal relationship from LGND graph: Reciprocal relationship from OVID graph: Reciprocal relationship from LGND g…
ndensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arisi…
Reciprocal relationship from LGND graph: Reciprocal relationship from OVID graph: ndensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and…
GRAVITON-BIOSCIENCE-CORPORATION
GRAVITON-BIOSCIENCE-CORPORATION
62%
year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with maturities of greater than twelve months as nonc…
M13-THERAPEUTICS-INC
M13-THERAPEUTICS-INC
62%
year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with maturities of greater than twelve months as nonc…
OVID-THERAPEUTICS-AUSTRALIA-PTY-LTD
OVID-THERAPEUTICS-AUSTRALIA-PTY-LTD
62%
olidated financial statements. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed will have a negative impa…
OVID-THERAPEUTICS-HONG-KONG-LTD
OVID-THERAPEUTICS-HONG-KONG-LTD
62%
olidated financial statements. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed will have a negative impa…
TAKEDA-COMPANY-LIMITED
TAKEDA-COMPANY-LIMITED
62%
approval for and commercialize our drug candidates, or successfully develop any other drug candidates, or experience significant delays in doing so, our business will be harmed. We are early in our d…
Ovid Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OVID-DEBT-11627
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
OVID-DEBT-59802
Warrants outstanding: 1.09
90%
xbrl warrant detail from xbrl 2026-03-31.
OVID-DEBT
Debt stack $13.1M
90%
Market cache reports total debt of $13.1M.
Ovid Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Ovid Therapeutics Inc..
Ovid Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
OVID-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 104 tracked holders.
Ovid Therapeutics Inc. Extended Supply Chain Network
